

subject, thereby modulating dosage of said virally encoded transgene.

52. (Added) A pharmaceutical composition comprising a viral nucleic acid encoding a therapeutic gene product, an agent that modulates Kupffer cell function, and a pharmaceutically acceptable carrier.

53. (Added) The pharmaceutical composition according to claim 52, wherein said viral nucleic acid is provided in a viral particle.

54. (Added) The method according to claim 1, wherein said first and/or second viral vector is a replication-defective viral vector.

REMARKS

Applicants have updated the related application information by amendment of the first paragraph beneath the Title on page 1. Applicants have canceled claims 2-33 without prejudice and without waiver of their right to pursue any canceled subject matter in a divisional or continuing applications claiming priority from this application or a related application.

Applicants have amended claim 1. Support for amended claim 1 is found, e.g., in original claims 1 and 8. Applicants have added claims 34-53. Support for claims 34-35 is found, e.g., in original claims 1, 10 and 12-13. Support for claim 36 is found, e.g., in original

claims 1 and 14. Support for claim 37 is found, e.g., in original claims 1 and 15-16. Support for claim 38-39 is found, e.g., in the Specification at page 12, line 4-5 and page 11, lines 13-16 and original claims 1, 2 and 9. the Specification at page 12, line 4-5 and page 11, lines 13-16 and original claims 1, 2 and 9. Support for claim 40 is found, e.g., in original claims 1 and 17. Support for claim 41-42 is found, e.g., in original claims 1, 18-19 and the Specification at page 16, lines 18-23. Support for claim 43-45 is found, e.g., in original claims 1, and 20-22. Support for claim 46 and 54 are found, e.g., in original claims 1, 8 and 24 and original claim 23 and the Specification at page 11, line 16-17. Support for claim 47-49 is found, e.g., in original claims 27-29. Support for claim 50 is found, e.g., in original claim 30. Support for claim 51 is found, e.g., in original claim 31. Support for claim 52 is found, e.g., in original claim 32. Support for claim 53 is found, e.g., in original claims 1 and 33.

None of the above-listed amendments to the claims goes beyond the disclosure in the application as filed.

CONCLUSION

Applicants request early allowance of the pending claims.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Stanley D. Liang (Reg. No. 43,753)
Attorneys for Applicants
Kyumin K. Lee (Reg. No. 53,195)
Agent for Applicants
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020
Tel.: (212) 596-9000
Fax: (212) 596-9090